You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

19 Results
Guidelines and Advice
Status: Current
ID: PET 10
Jan 2009
Guidelines and Advice
Status: Current
ID: PET 9
Jan 2009
Guidelines and Advice
Status: Current
ID: PET 8
Jan 2009
Guidelines and Advice
Status: Current
ID: PET 7
Jan 2009
Guidelines and Advice
Status: Current
ID: PET 6
Jan 2009
Guidelines and Advice
Status: Current
ID: PET 5
Jan 2009
Guidelines and Advice
Status: Current
ID: PET 3
Jan 2009
Guidelines and Advice
Status: Current
ID: GL-C50-27
Nov 2021
Guidelines and Advice
Status: Current
ID: GL-C50-32
Jan 2021
Drug
Other Name(s): Ibrance™
Quick Link(s):
Drug Monograph, Patient Info Sheet
May 2021
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Show More Show more tags
, Show Less Show fewer tags
Intent: Adjuvant, Curative, Palliative
Drugs Used:
pemetrexed
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Aug 2021
Regimen
Cancer Type:
Gynecologic, 
Cervix
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Bevacizumab (Biosimilar) - Metastatic (Stage IVB), Persistent, or Recurrent Carcinoma of the Cervix
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
PACLitaxel,
topotecan,
bevacizumab
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jun 2021

Pages